MedTrace Logo

Gene Transfer for HIV Using Autologous T Cells

NCT01153646 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2011-01-19

No results posted yet for this study

Summary

This is a pilot study to determine the safety and feasibility of lentivirus-transduced T-cell immunotherapy in patients who have failed highly active anti-retrovirus therapy (HAART).

Conditions

  • HIV-1 Infection

Interventions

GENETIC

pHIV7-shI-TAR-CCR5RZ treated CD4 cells

Single dose administration x 3 of genetically modified T-cells given at 3 infusions at 6 week intervals.

Sponsors & Collaborators

  • City of Hope Medical Center

    lead OTHER

Principal Investigators

  • John A. Zaia, MD · Beckman Research Institute of City of Hope

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01153646 on ClinicalTrials.gov